Published in Thromb Res on October 24, 2009
Microparticles in hemostasis and thrombosis. Circ Res (2011) 2.26
The polyphosphate-factor XII pathway drives coagulation in prostate cancer-associated thrombosis. Blood (2015) 1.69
Proteomics of microparticles after deep venous thrombosis. Thromb Res (2010) 1.50
PF4/heparin-antibody complex induces monocyte tissue factor expression and release of tissue factor positive microparticles by activation of FcγRI. Blood (2012) 1.48
Association between cell-derived microparticles and adverse events in patients with nonpulsatile left ventricular assist devices. J Heart Lung Transplant (2014) 1.46
Tissue factor expressed by circulating cancer cell-derived microparticles drastically increases the incidence of deep vein thrombosis in mice. J Thromb Haemost (2015) 1.46
A novel pathway of cellular activation mediated by antiphospholipid antibody-induced extracellular vesicles. J Thromb Haemost (2015) 1.40
New insights into the mechanisms of venous thrombosis. J Clin Invest (2012) 1.32
Microparticles: a critical component in the nexus between inflammation, immunity, and thrombosis. Semin Immunopathol (2011) 1.26
Pre-analytical and analytical variables affecting the measurement of plasma-derived microparticle tissue factor activity. Thromb Res (2011) 1.25
Tumor-derived tissue factor activates coagulation and enhances thrombosis in a mouse xenograft model of human pancreatic cancer. Blood (2012) 1.20
Tumor-derived tissue factor-positive microparticles and venous thrombosis in cancer patients. Blood (2013) 1.19
Association of coagulation activation with clinical complications in sickle cell disease. PLoS One (2012) 1.17
Circulating microparticles: square the circle. BMC Cell Biol (2013) 1.14
Role of tissue factor in venous thrombosis. Annu Rev Physiol (2011) 1.09
Tissue factor-positive monocytes in children with sickle cell disease: correlation with biomarkers of haemolysis. Br J Haematol (2012) 0.95
Clinical significance of procoagulant microparticles. J Intensive Care (2015) 0.94
Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study). Br J Haematol (2012) 0.91
Microparticle analysis in disorders of hemostasis and thrombosis. Cytometry A (2015) 0.89
A simple flow cytometry method improves the detection of phosphatidylserine-exposing extracellular vesicles. J Thromb Haemost (2014) 0.89
Thrombosis and cancer. Nat Rev Clin Oncol (2012) 0.88
Thrombin generation assay and transmission electron microscopy: a useful combination to study tissue factor-bearing microvesicles. J Extracell Vesicles (2013) 0.88
Role of tissue factor in thrombosis in antiphospholipid antibody syndrome. Lupus (2010) 0.86
Asymptomatic deep vein thrombosis and superficial vein thrombosis in ambulatory cancer patients: impact on short-term survival. Br J Cancer (2012) 0.86
Biomolecular markers of cancer-associated thromboembolism. Crit Rev Oncol Hematol (2013) 0.84
Tissue factor-positive tumor microvesicles activate platelets and enhance thrombosis in mice. J Thromb Haemost (2015) 0.81
A phase I clinical trial of bavituximab and paclitaxel in patients with HER2 negative metastatic breast cancer. Cancer Med (2015) 0.79
Plasma microparticle tissue factor activity in patients with antiphospholipid antibodies with and without clinical complications. Thromb Res (2013) 0.79
Physiological levels of blood coagulation factors IX and X control coagulation kinetics in an in vitro model of circulating tissue factor. Phys Biol (2013) 0.79
Tissue factor structure and function. Scientifica (Cairo) (2012) 0.78
Microparticles: new light shed on the understanding of venous thromboembolism. Acta Pharmacol Sin (2014) 0.78
Decrease in microvesicle-associated tissue factor activity in morbidly obese patients after bariatric surgery. Int J Obes (Lond) (2015) 0.77
Extracellular vesicles, tissue factor, cancer and thrombosis - discussion themes of the ISEV 2014 Educational Day. J Extracell Vesicles (2015) 0.77
Microparticles as Biomarkers of Blood Coagulation in Cancer. Biomark Cancer (2015) 0.77
Simulated Thrombin Generation in the Presence of Surface-Bound Heparin and Circulating Tissue Factor. Ann Biomed Eng (2015) 0.77
The role of thromboprophylaxis in cancer patients: emerging data. Curr Opin Hematol (2010) 0.76
Predictive value of microparticle-associated tissue factor activity for permeability glycoprotein-mediated multidrug resistance in cancer. Oncol Lett (2016) 0.75
Phosphatidylserine exposing-platelets and microparticles promote procoagulant activity in colon cancer patients. J Exp Clin Cancer Res (2016) 0.75
Cancer and Thrombosis: The Platelet Perspective. Front Cell Dev Biol (2017) 0.75
New prognostic biomarkers and therapeutic effect of bevacizumab for patients with non-small-cell lung cancer. Lung Cancer (Auckl) (2017) 0.75
Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost (2007) 3.22
Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes. Blood (2003) 3.04
Microparticle-associated tissue factor activity: a link between cancer and thrombosis? J Thromb Haemost (2006) 3.03
High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood (2008) 2.97
Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nat Med (2003) 2.93
Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterioscler Thromb Vasc Biol (2007) 2.70
Tissue factor-positive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer. Thromb Haemost (2007) 2.56
Inflammation and liver cancer: new molecular links . Ann N Y Acad Sci (2009) 2.29
Procoagulant microparticles: disrupting the vascular homeostasis equation? Arterioscler Thromb Vasc Biol (2006) 2.23
Induction of microparticle- and cell-associated intravascular tissue factor in human endotoxemia. Blood (2004) 1.82
D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol (2009) 1.78
Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer. J Thromb Haemost (2008) 1.70
Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer. Br J Cancer (2007) 1.60
Risk factors for venous thromboembolic events in cancer patients. Ann Oncol (2005) 1.32
Microparticle-associated tissue factor activity in cancer patients with and without thrombosis. J Thromb Haemost (2009) 1.19
Targeting patients for anticoagulant prophylaxis trials in patients with cancer: who is at highest risk? Thromb Res (2007) 0.93
The role of D-dimer and residual venous obstruction in recurrence of venous thromboembolism after anticoagulation withdrawal in cancer patients. Haematologica (2005) 0.92
HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell (2003) 9.12
Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol (2013) 5.56
The phosphatidylinositol 3-kinase-Akt pathway limits lipopolysaccharide activation of signaling pathways and expression of inflammatory mediators in human monocytic cells. J Biol Chem (2002) 4.28
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet (2008) 3.74
Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med (2012) 3.63
Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C. J Exp Med (2007) 3.35
Macrovascular thrombosis is driven by tissue factor derived primarily from the blood vessel wall. Blood (2004) 3.31
Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes. Blood (2003) 3.04
The ITP syndrome: pathogenic and clinical diversity. Blood (2009) 2.83
Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterioscler Thromb Vasc Biol (2007) 2.70
Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood (2004) 2.41
Protein disulfide isomerase acts as an injury response signal that enhances fibrin generation via tissue factor activation. J Clin Invest (2008) 2.39
Signal-dependent splicing of tissue factor pre-mRNA modulates the thrombogenicity of human platelets. J Exp Med (2006) 2.39
TLR2 is constitutively expressed within the kidney and participates in ischemic renal injury through both MyD88-dependent and -independent pathways. J Immunol (2007) 2.32
Microparticles in hemostasis and thrombosis. Circ Res (2011) 2.26
Comparison of characteristics from White- and Black-Americans with venous thromboembolism: a cross-sectional study. Am J Hematol (2010) 2.26
Role of tissue factor and protease-activated receptors in a mouse model of endotoxemia. Blood (2003) 2.20
Hematopoietic cell-derived microparticle tissue factor contributes to fibrin formation during thrombus propagation. Blood (2004) 2.16
Hematopoietic and nonhematopoietic cell tissue factor activates the coagulation cascade in endotoxemic mice. Blood (2010) 2.10
Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res (2009) 2.04
The thrombomodulin-protein C system is essential for the maintenance of pregnancy. Nat Med (2003) 1.98
Protease-activated receptor-1 contributes to cardiac remodeling and hypertrophy. Circulation (2007) 1.97
Sickle cell trait and the risk of venous thromboembolism among blacks. Blood (2007) 1.95
Role of tissue factor in cancer. J Clin Oncol (2009) 1.91
Regulation of tissue factor--mediated initiation of the coagulation cascade by cell surface grp78. Arterioscler Thromb Vasc Biol (2005) 1.82
Induction of microparticle- and cell-associated intravascular tissue factor in human endotoxemia. Blood (2004) 1.82
Genetic analysis of the role of the PI3K-Akt pathway in lipopolysaccharide-induced cytokine and tissue factor gene expression in monocytes/macrophages. J Immunol (2008) 1.74
Hypercoagulability in sickle cell disease: new approaches to an old problem. Hematology Am Soc Hematol Educ Program (2007) 1.65
PI3K-Akt pathway suppresses coagulation and inflammation in endotoxemic mice. Arterioscler Thromb Vasc Biol (2004) 1.65
Chlamydia pneumoniae induces tissue factor expression in mouse macrophages via activation of Egr-1 and the MEK-ERK1/2 pathway. Circ Res (2003) 1.59
D-dimer antigen: current concepts and future prospects. Blood (2008) 1.59
Andrographolide attenuates inflammation by inhibition of NF-kappa B activation through covalent modification of reduced cysteine 62 of p50. J Immunol (2004) 1.58
Factor Xa binding to annexin 2 mediates signal transduction via protease-activated receptor 1. Circ Res (2008) 1.55
Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease. Blood (2014) 1.53
Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin. J Clin Invest (2012) 1.51
Protease-activated receptor-2 regulates the innate immune response to viral infection in a coxsackievirus B3-induced myocarditis. J Am Coll Cardiol (2013) 1.50
Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury. Blood (2007) 1.49
PF4/heparin-antibody complex induces monocyte tissue factor expression and release of tissue factor positive microparticles by activation of FcγRI. Blood (2012) 1.48
Platelet microparticles are heterogeneous and highly dependent on the activation mechanism: studies using a new digital flow cytometer. Cytometry A (2007) 1.48
Monocytic microparticles activate endothelial cells in an IL-1β-dependent manner. Blood (2011) 1.48
Critical review of mouse models of venous thrombosis. Arterioscler Thromb Vasc Biol (2012) 1.46
Major burn injury is not associated with acute traumatic coagulopathy. J Trauma Acute Care Surg (2013) 1.43
Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. Blood (2011) 1.43
Thromboembolic complications of cancer: epidemiology, pathogenesis, diagnosis, and treatment. Am J Hematol (2003) 1.41
Lipopolysaccharide-induced heme oxygenase-1 expression in human monocytic cells is mediated via Nrf2 and protein kinase C. J Immunol (2005) 1.36
Tissue factor-positive neutrophils bind to injured endothelial wall and initiate thrombus formation. Blood (2012) 1.34
Ptpn11 deletion in a novel progenitor causes metachondromatosis by inducing hedgehog signalling. Nature (2013) 1.33
Vascular smooth muscle-derived tissue factor is critical for arterial thrombosis after ferric chloride-induced injury. Blood (2008) 1.32
Role of tissue factor in haemostasis, thrombosis, angiogenesis and inflammation: lessons from low tissue factor mice. Thromb Haemost (2004) 1.28
A balance between tissue factor and tissue factor pathway inhibitor is required for embryonic development and hemostasis in adult mice. Blood (2004) 1.26
Thyroid disease in patients with immune thrombocytopenia. Hematol Oncol Clin North Am (2009) 1.24
Platelet ITAM signaling is critical for vascular integrity in inflammation. J Clin Invest (2013) 1.24
Blood coagulation: hemostasis and thrombin regulation. Anesth Analg (2009) 1.24
Role of the coagulation system in acetaminophen-induced hepatotoxicity in mice. Hepatology (2007) 1.23
Neutrophil activation by the tissue factor/Factor VIIa/PAR2 axis mediates fetal death in a mouse model of antiphospholipid syndrome. J Clin Invest (2008) 1.23
High prevalence of sickle cell trait in African Americans with ESRD. J Am Soc Nephrol (2010) 1.23
Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity. Cancer Res (2009) 1.22
Tissue factor in hemostasis and thrombosis. Semin Thromb Hemost (2006) 1.21
Unsuspected pulmonary emboli in cancer patients: clinical correlates and relevance. J Clin Oncol (2006) 1.21
Tumor-derived tissue factor activates coagulation and enhances thrombosis in a mouse xenograft model of human pancreatic cancer. Blood (2012) 1.20
Molecular epidemiology of measles viruses in China, 1995-2003. Virol J (2007) 1.20
Tissue factor regulation by epidermal growth factor receptor and epithelial-to-mesenchymal transitions: effect on tumor initiation and angiogenesis. Cancer Res (2008) 1.19
Tumor-derived tissue factor-positive microparticles and venous thrombosis in cancer patients. Blood (2013) 1.19
Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, part 2: Treatment. Am J Hematol (2009) 1.18
Factor XIII activity mediates red blood cell retention in venous thrombi. J Clin Invest (2014) 1.18
Tissue factor deficiency and PAR-1 deficiency are protective against renal ischemia reperfusion injury. Blood (2006) 1.18
Association of coagulation activation with clinical complications in sickle cell disease. PLoS One (2012) 1.17
Tissue factor and its measurement in whole blood, plasma, and microparticles. Semin Thromb Hemost (2010) 1.17
Oncogenes, trousseau syndrome, and cancer-related changes in the coagulome of mice and humans. Cancer Res (2006) 1.16
COX-2 suppresses tissue factor expression via endocannabinoid-directed PPARdelta activation. J Exp Med (2007) 1.16
Tissue factor and thrombosis: The clot starts here. Thromb Haemost (2010) 1.16
Early growth response gene-1 regulates hypoxia-induced expression of tissue factor in glioblastoma multiforme through hypoxia-inducible factor-1-independent mechanisms. Cancer Res (2006) 1.13
Tissue factor, coagulation proteases, and protease-activated receptors in endotoxemia and sepsis. Crit Care Med (2004) 1.12
Hepatitis C virus-related thrombocytopenia: clinical and laboratory characteristics compared with chronic immune thrombocytopenic purpura. Br J Haematol (2005) 1.12
Role of procoagulant microparticles in mediating complications and outcome of acute liver injury/acute liver failure. Hepatology (2013) 1.11
Induction of tissue factor expression in human endothelial cells by CD40 ligand is mediated via activator protein 1, nuclear factor kappa B, and Egr-1. J Biol Chem (2002) 1.11
Plasma protein profiling: unique and stable features of individuals. Proteomics (2005) 1.11
Regulation of tissue factor and inflammatory mediators by Egr-1 in a mouse endotoxemia model. Blood (2003) 1.11
IGFBP-rP1 induces p21 expression through a p53-independent pathway, leading to cellular senescence of MCF-7 breast cancer cells. J Cancer Res Clin Oncol (2012) 1.10
Role of tissue factor in venous thrombosis. Annu Rev Physiol (2011) 1.09
Cellular sources of tissue factor in endotoxemia and sepsis. Thromb Res (2010) 1.09
PAR-1 contributes to the innate immune response during viral infection. J Clin Invest (2013) 1.09
Transcriptional regulation of EGR-1 by the interleukin-1-JNK-MKK7-c-Jun pathway. J Biol Chem (2008) 1.08
Contribution of host-derived tissue factor to tumor neovascularization. Arterioscler Thromb Vasc Biol (2008) 1.08
Hemostatic abnormalities in sickle cell disease. Curr Opin Hematol (2013) 1.08
Adjuvant chemotherapy and radiotherapy in triple-negative breast carcinoma: a prospective randomized controlled multi-center trial. Radiother Oncol (2011) 1.07
Insulin activation of the phosphatidylinositol 3-kinase/protein kinase B (Akt) pathway reduces lipopolysaccharide-induced inflammation in mice. J Pharmacol Exp Ther (2008) 1.07
Tissue factor-dependent coagulation contributes to alpha-naphthylisothiocyanate-induced cholestatic liver injury in mice. Am J Physiol Gastrointest Liver Physiol (2009) 1.07
Effects of tissue factor, thrombomodulin and elevated clotting factor levels on thrombin generation in the calibrated automated thrombogram. Thromb Haemost (2009) 1.07
Study of Apiosoma piscicola (Blanchard 1885) occurring on fry of freshwater fishes in Hongze, China with consideration of the genus Apiosoma. Parasitol Res (2008) 1.06
Chemisorption of CO2 on nickel surfaces. J Phys Chem B (2005) 1.06
Tissue Factor and Atherothrombosis. J Atheroscler Thromb (2015) 1.05